文献速递乳腺癌

CLEOPATRA研究终末分析:帕妥珠单抗联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
PubMed 文献 · Lancet Oncol · 2020-03-12

CLEOPATRA是一项双盲、随机、安慰剂对照3期研究,在808例HER2阳性转移性乳腺癌患者中比较帕妥珠单抗+曲妥珠单抗+多西他赛与安慰剂+曲妥珠单抗+多西他赛。

要点

  • 8年总生存率帕妥珠单抗组37%,对照组23%。
  • 长期安全性和心脏安全性在总体安全人群和交叉患者中维持。

核心结论

  • 在中位随访超过8年后,帕妥珠单抗联合曲妥珠单抗和多西他赛较安慰剂联合方案的总生存获益维持。
  • 长期安全性和心脏安全性在总体安全人群和交叉患者中维持。

研究设计与样本

  • 双盲、随机、安慰剂对照3期研究,在25个国家204个中心进行。
  • 入组808例HER2阳性转移性乳腺癌患者,随机1:1分配至帕妥珠单抗组(402例)或安慰剂组(406例)。
  • 分层因素为地理区域和既往辅助/新辅助化疗史;主要终点为独立评审机构评估的无进展生存期。

主要发现

  • 8年里程碑总生存率帕妥珠单抗组37%(95%CI 31-42),安慰剂组23%(95%CI 19-28)。
  • 最常见3-4级不良事件为中性粒细胞减少:帕妥珠单抗组200/408例(49%),安慰剂组183/396例(46%)。
  • 治疗相关死亡:帕妥珠单抗组5/408例(1%),安慰剂组6/396例(2%)。
  • 自上次分析以来新发1例严重不良事件提示充血性心力衰竭(帕妥珠单抗组)和1例症状性左心室收缩功能障碍(交叉后)。

临床怎么用

  • 对于既往未接受过转移性疾病化疗或生物治疗的HER2阳性转移性乳腺癌患者,帕妥珠单抗联合曲妥珠单抗和多西他赛方案具有长期总生存获益。
  • 该方案的长期安全性和心脏安全性特征在延长随访中维持。

局限性

  • 分析为描述性,总生存分析未对交叉至帕妥珠单抗组进行调整,结果可能偏保守。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. In the primary analysis and subsequent reports, progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group. Here, we report the end-of-study analysis of CLEOPATRA. METHODS: This was a double-blind, randomised, placebo-controlled, phase 3 trial that was done at 204 centres in 25 countries. Eligible patients were 18 years or older, had HER2-positive, metastatic breast cancer, had not received previous chemotherapy or biological treatment for their metastatic disease, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. All study drugs were given intravenously, every 3 weeks. Patients were assigned to receive either pertuzumab or placebo at a loading dose of 840 mg, and 420 mg thereafter; plus trastuzumab at 8 mg/kg loading dose and 6 mg/kg thereafter; and docetaxel at 75 mg/m2, escalating to 100 mg/m2 if tolerated. Pertuzumab or placebo and trastuzumab were given until disease progression; docetaxel was given for six cycles, or longer at the investigators' discretion. Randomisation (1:1) was done by use of an interactive voice-response system and was stratified by geographical region (Asia, Europe, North America, or South America) and previous treatment (previous adjuvant or neoadjuvant chemotherapy vs none). The primary endpoint was independent review facility-assessed progression-free survival, which has been reported previously. Since the confirmatory overall survival analysis had also occurred before this prespecified end-of-study analysis, analyses presented here are descriptive. Overall survival analyses were based on the intention-to-treat population with crossover patients analysed in the placebo group; analyses were not adjusted for crossover to the pertuzumab group and are likely to be conservative. Safety analyses were based on treatment received; crossover patients were counted in the placebo group up to the day before first pertuzumab dose. This trial is registered with ClinicalTrials.gov, number NCT00567190. FINDINGS: Between Feb 12, 2008, and July 7, 2010, 1196 patients were assessed for eligibility, of whom 808 were enrolled and randomly assigned. 402 patients were assigned to receive docetaxel plus trastuzumab plus pertuzumab, and 406 patients were assigned to receive docetaxel plus trastuzumab plus placebo. Clinical cutoff for this analysis was Nov 23, 2018. Between July 2012 and clinical cutoff, 50 patients crossed from the placebo to the pertuzumab group. Median follow-up was 99·9 months in the pertuzumab group (IQR 92·9-106·4) and 98·7 months (90·9-105·7) in the placebo group. Median overall survival was 57·1 months (95% CI 50-72) in the pertuzumab group and 40·8 months (36-48) in the placebo group (hazard ratio 0·69, 95% CI 0·58-0·82); 8-year landmark overall survival rates were 37% (95% CI 31-42) in the pertuzumab group and 23% (19-28) in the placebo group. The most common grade 3-4 adverse event was neutropenia (200 [49%] of 408 patients in the pertuzumab group, 183 [46%] of 396 patients in the placebo group). Five (1%) of 408 patients in the pertuzumab group and six (2%) of 396 patients in the placebo group had treatment-related deaths. One new serious adverse event suggestive of congestive heart failure (pertuzumab group) and one new symptomatic left ventricular systolic dysfunction (post-crossover) occurred since the previous analysis. INTERPRETATION: Our analysis shows that the previously observed improvements in overall survival with pertuzumab, trastuzumab, and docetaxel versus placebo, trastuzumab, and docetaxel were maintained after a median of more than 8 years of follow-up. The long-term safety and cardiac safety profiles of pertuzumab, trastuzumab, and docetaxel were maintained in the overall safety population and within crossover patients. HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%. FUNDING: F Hoffmann-La Roche and Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020. PMID: 32171426. doi:10.1016/S1470-2045(19)30863-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。